Quantcast

Latest Cisplatin Stories

2011-07-12 22:35:33

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that a low dose of the opioid antagonist naltrexone (LDN) has an extraordinarily potent antitumor effect on human ovarian cancer in tissue culture and xenografts established in nude mice. When LDN is combined with chemotherapy, there is an additive inhibitory action on tumorigenesis. This discovery, reported in the July 2011 issue of Experimental Biology and Medicine, provides new...

2011-06-05 08:00:00

INDIANAPOLIS, June 5, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that PARAMOUNT, its Phase III study evaluating ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, met its primary endpoint of progression-free survival, or the time a patient is alive without their disease worsening, for patients with a specific type of lung cancer called advanced nonsquamous non-small cell lung cancer (NSCLC). "Continuation maintenance"...

2011-06-01 22:58:25

Cisplatin is one of the most widely used anticancer chemotherapeutics. However, it has some severe side effects in normal tissues, in particular it is toxic to the kidneys. Understanding the mechanisms underlying this toxicity could identify targets for drugs that could be given together with cisplatin to protect the kidney during chemotherapy. In this context, a team of researchers, led by Zheng Dong, at Georgia Health Sciences University, Augusta, has now identified the signaling protein...

2011-03-24 21:00:40

Research led by Daitoku Sakamuro, PhD, Assistant Professor of Pathology at LSU Health Sciences Center New Orleans and the LSUHSC Stanley S. Scott Cancer Center, has identified a protein that enables the activation of a DNA-repair enzyme that protects cancer cells from catastrophic damage caused by chemo and radiation therapy. This protein, called c-MYC oncoprotein, can initiate and promote almost all human cancers and discovering the role it plays in cancer treatment resistance may lead to...

2011-03-21 08:00:00

SAN DIEGO, March 21, 2011 /PRNewswire/ -- Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer. The publication is now available on the International Journal of Gynecological Cancer website and scheduled to print in the...

2011-02-02 08:42:00

INDIANAPOLIS and PRINCETON, N.J., Feb. 2, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC). (Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO ) The randomized, multi-center, open-label Phase III trial,...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related